ENXTPA:ABVXBiotechs
ABIVAX (ENXTPA:ABVX) Q3 2025 Loss Surges to €153m, Reinforcing Cash-Burn Concerns
ABIVAX Société Anonyme (ENXTPA:ABVX) has just posted its Q3 2025 numbers, with revenue of about €2.0 million and a basic EPS of roughly -€2.10, while trailing 12 month figures sit at €6.8 million in revenue and EPS of around -€4.46. The company has seen revenue hover in a narrow band between about €0.97 million and €2.0 million over the last few quarters, while EPS has remained firmly negative throughout that stretch. This highlights a story driven more by pipeline progress than by near term...